Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   35504   clinical trials with a EudraCT protocol, of which   5838   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    Relative bioavailability study to investigate the pharmacokinetics, safety and tolerability of a single oral dose of finerenone 20 mg as suspension (pediatric formulation), intact tablet and crushed tablet (adult formulation) in the fasting condition, and to investigate the effect of a high fat, high calorie meal on the suspension in healthy male subjects in a randomized, open-label, four-fold crossover design

    Summary
    EudraCT number
    2016-002813-24
    Trial protocol
    DE  
    Global end of trial date
    01 Mar 2017

    Results information
    Results version number
    v1(current)
    This version publication date
    25 Jan 2018
    First version publication date
    25 Jan 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    BAY94-8862/16538
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT02957396
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Bayer AG
    Sponsor organisation address
    Kaiser-Wilhelm-Allee, D-51368 Leverkusen, Germany,
    Public contact
    Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
    Scientific contact
    Therapeutic Area Head, Bayer AG, clinical-trials-contact@bayer.com
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    Yes
    EMA paediatric investigation plan number(s)
    EMEA-001623-PIP01-14
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Mar 2017
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Mar 2017
    Was the trial ended prematurely?
    No
    General information about the trial
    Main objective of the trial
    The primary objectives of this study were to 1. investigate the relative bioavailability of a single oral dose of 20 milligram (mg) finerenone suspension and 20 mg crushed and re-suspended tablet in comparison to 20 mg finerenone tablet in the fasting condition; 2. investigate the effect of a high fat, high calorie meal on the pharmacokinetics (PK) of a single oral dose of 20 mg finerenone suspension; 3. investigate whether 20 mg finerenone suspension and 20 mg crushed and re-suspended tablet are palatable and swallowable by using a questionnaire regarding overall impression, appearance, smell, taste, texture, and swallowability.
    Protection of trial subjects
    The conduct of this clinical study met all local legal and regulatory requirements. The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the International Conference on Harmonization guideline E6: Good Clinical Practice. Before entering the study, the informed consent form was read by and explained to all subjects. Participating subjects signed informed consent form and could withdraw from the study at any time without any disadvantage and without having to provide a reason for this decision. Only investigators qualified by training and experience were selected as appropriate experts to investigate the study drug.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    17 Nov 2016
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    No
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Germany: 16
    Worldwide total number of subjects
    16
    EEA total number of subjects
    16
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    16
    From 65 to 84 years
    0
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    Study was conducted at one study center in Germany, between 17 November 2016 (first subject first visit) and 13 January 2017 (last subject last visit).

    Pre-assignment
    Screening details
    Overall, 36 subjects were enrolled, of them 20 subjects were not included into the study. A total of 16 subjects were randomized and received all the treatments in a four-fold cross-over fashion (A-D-C-B, B-C-D-A, C-A-B-D, or D-B-A-C) and completed the study.

    Period 1
    Period 1 title
    Overall Trial (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Not applicable
    Blinding used
    Not blinded

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Treatment A-D-C-B
    Arm description
    Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.
    Arm type
    Experimental

    Investigational medicinal product name
    Finerenone
    Investigational medicinal product code
    BAY94-8862
    Other name
    Pharmaceutical forms
    Film-coated tablet, Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state. Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state. Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state. Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state.

    Arm title
    Treatment B-C-D-A
    Arm description
    Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.
    Arm type
    Experimental

    Investigational medicinal product name
    Finerenone
    Investigational medicinal product code
    BAY94-8862
    Other name
    Pharmaceutical forms
    Film-coated tablet, Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state. Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state. Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state. Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state.

    Arm title
    Treatment C-A-B-D
    Arm description
    Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.
    Arm type
    Experimental

    Investigational medicinal product name
    Finerenone
    Investigational medicinal product code
    BAY94-8862
    Other name
    Pharmaceutical forms
    Film-coated tablet, Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state. Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state. Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state. Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state.

    Arm title
    Treatment D-B-A-C
    Arm description
    Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.
    Arm type
    Experimental

    Investigational medicinal product name
    Finerenone
    Investigational medicinal product code
    BAY94-8862
    Other name
    Pharmaceutical forms
    Film-coated tablet, Oral suspension
    Routes of administration
    Oral use
    Dosage and administration details
    Treatment D: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state. Treatment B: Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state. Treatment A: Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state. Treatment C: Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state.

    Number of subjects in period 1
    Treatment A-D-C-B Treatment B-C-D-A Treatment C-A-B-D Treatment D-B-A-C
    Started
    4
    4
    4
    4
    Completed
    4
    4
    4
    4

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Treatment A-D-C-B
    Reporting group description
    Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment B-C-D-A
    Reporting group description
    Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment C-A-B-D
    Reporting group description
    Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment D-B-A-C
    Reporting group description
    Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group values
    Treatment A-D-C-B Treatment B-C-D-A Treatment C-A-B-D Treatment D-B-A-C Total
    Number of subjects
    4 4 4 4 16
    Age Categorical
    Units: Subjects
    Age Continuous
    Units: years
        arithmetic mean (standard deviation)
    35.3 ± 7.3 35.3 ± 7.0 36.8 ± 5.0 36.8 ± 10.9 -
    Gender Categorical
    Units: Subjects
        Male
    4 4 4 4 16

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Treatment A-D-C-B
    Reporting group description
    Subjects who followed treatment sequence A-D-C-B in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone (BAY94-8862) intact film-coated tablet in fasted state (Treatment A) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 milliliter [mL]) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the third intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment B-C-D-A
    Reporting group description
    Subjects who followed treatment sequence B-C-D-A in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the first intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the second intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the third intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment C-A-B-D
    Reporting group description
    Subjects who followed treatment sequence C-A-B-D in fasted and fed state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the first intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the second intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Reporting group title
    Treatment D-B-A-C
    Reporting group description
    Subjects who followed treatment sequence D-B-A-C in fed and fasted state were reported. Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state (Treatment D) in the first intervention period; followed by a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state (Treatment B) in the second intervention period; followed by a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state (Treatment A) in the third intervention period; followed by a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state (Treatment C) in the fourth intervention period. A wash-out period of at least 72 hours was maintained between finerenone administrations.

    Subject analysis set title
    Safety analysis set (SAF)
    Subject analysis set type
    Safety analysis
    Subject analysis set description
    SAF (N=16) included all subjects who received at least one dose of the study medication.

    Subject analysis set title
    Pharmacokinetic analysis set (PKS)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    PKS (N=16) included all subjects with a valid PK profile for at least two of the treatments relevant for comparison (Treatment A and B or Treatment A and C or Treatment C and D).

    Subject analysis set title
    Finerenone 20 mg Intact Tablet Fasted (Treatment A)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Subjects (N=16) received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state during any intervention period.

    Subject analysis set title
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Subjects (N=16) received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state during any intervention period.

    Subject analysis set title
    Finerenone 20 mg Suspension Fasted (Treatment C)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Subjects (N=16) received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state during any intervention period.

    Subject analysis set title
    Finerenone 20 mg Suspension Fed (Treatment D)
    Subject analysis set type
    Sub-group analysis
    Subject analysis set description
    Subjects (N=16) received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state during any intervention period.

    Primary: Maximum Observed Concentration (Cmax) After Single Dose Administration of Finerenone in Plasma

    Close Top of page
    End point title
    Maximum Observed Concentration (Cmax) After Single Dose Administration of Finerenone in Plasma
    End point description
    Maximum observed concentration of finerenone in plasma after single dose administration was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
    End point type
    Primary
    End point timeframe
    Pre-dose to 24 hours post-dose
    End point values
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16
    16
    16
    16
    Units: microgram per liter (mcg/L)
        geometric mean (geometric coefficient of variation)
    154 ± 29.9
    138 ± 35.9
    190 ± 32.3
    110 ± 27.3
    Statistical analysis title
    Statistical analysis: Treatment (C)/Treatment (A)
    Statistical analysis description
    Cmax of finerenone were analyzed using analysis of variance (ANOVA) including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (least squares (LS)-means) and exploratory 90 percent (%) confidence intervals (CIs) for the ratios “20 mg suspension fasted (C)/20 mg intact tablet fasted (A)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
    Comparison groups
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Suspension Fasted (Treatment C)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in percent [%]
    Point estimate
    122.9
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    104.48
         upper limit
    144.56
    Statistical analysis title
    Statistical analysis: Treatment (D)/Treatment (C)
    Statistical analysis description
    Cmax of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fed (D)/20 mg suspension fasted (C)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
    Comparison groups
    Finerenone 20 mg Suspension Fasted (Treatment C) v Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in %
    Point estimate
    58.02
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    49.32
         upper limit
    68.25
    Statistical analysis title
    Statistical analysis: Treatment (B)/Treatment (A)
    Statistical analysis description
    Cmax of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg crushed/re-suspended tablet fasted (B)/20 mg intact tablet fasted (A)” of Cmax were calculated. Database auto-calculate number of subjects analysed, but the actual number of subjects analysed was 16.
    Comparison groups
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in %
    Point estimate
    89.04
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    75.69
         upper limit
    104.74

    Primary: Area Under Concentration Versus Time Curve From Zero to Infinity (AUC) After Single Dose Administration of Finerenone in Plasma

    Close Top of page
    End point title
    Area Under Concentration Versus Time Curve From Zero to Infinity (AUC) After Single Dose Administration of Finerenone in Plasma
    End point description
    Area under the concentration versus time curve from zero to infinity after single dose administration of finerenone in plasma was measured. Geometric mean and percentage geometric coefficient of variation (%CV) were reported.
    End point type
    Primary
    End point timeframe
    Pre-dose to 24 hours post-dose
    End point values
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [1]
    16 [2]
    16 [3]
    16 [4]
    Units: microgram * hour per liter (mcg*h/L)
        geometric mean (geometric coefficient of variation)
    432 ± 33.0
    352 ± 37.7
    451 ± 28.7
    453 ± 26.4
    Notes
    [1] - PKS
    [2] - PKS
    [3] - PKS
    [4] - PKS
    Statistical analysis title
    Statistical analysis: Treatment (C)/Treatment (A)
    Statistical analysis description
    AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fasted (C)/20 mg intact tablet fasted (A)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
    Comparison groups
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Suspension Fasted (Treatment C)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in %
    Point estimate
    104.55
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    95.85
         upper limit
    114.04
    Statistical analysis title
    Statistical analysis: Treatment (B)/Treatment (A)
    Statistical analysis description
    AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg crushed/re-suspended tablet fasted (B)/20 mg intact tablet fasted (A)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
    Comparison groups
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) v Finerenone 20 mg Crushed Tablet Fasted (Treatment B)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in %
    Point estimate
    81.61
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    74.82
         upper limit
    89.02
    Statistical analysis title
    Statistical analysis: Treatment (D)/Treatment (C)
    Statistical analysis description
    AUC of finerenone were analyzed using ANOVA including sequence, subject (sequence), period, and treatment effects. Based on these analysis point estimates (LS-means) and exploratory 90% CIs for the ratios “20 mg suspension fed (D)/20 mg suspension fasted (C)” of AUC were calculated. Database auto calculate number of subjects analyzed, but the actual number of subjects analyzed was 16.
    Comparison groups
    Finerenone 20 mg Suspension Fasted (Treatment C) v Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects included in analysis
    32
    Analysis specification
    Pre-specified
    Analysis type
    other
    Method
    ANOVA
    Parameter type
    Estimated ratio in %
    Point estimate
    100.37
    Confidence interval
         level
    90%
         sides
    2-sided
         lower limit
    92.02
         upper limit
    109.48

    Secondary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)

    Close Top of page
    End point title
    Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)
    End point description
    An adverse event (AE) was any untoward medical occurrence in subject who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect and another serious or important medical event as judged by the investigator. AE/SAEs that started or worsened after study drug treatment were recorded as TEAE/TESAEs.
    End point type
    Secondary
    End point timeframe
    From start of study drug administration up to 1 week after last drug administration (Day 16)
    End point values
    Finerenone 20 mg Intact Tablet Fasted (Treatment A) Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [5]
    16 [6]
    16 [7]
    16 [8]
    Units: subjects
        TEAE
    2
    2
    3
    4
        TESAE
    0
    0
    0
    0
    Notes
    [5] - SAF
    [6] - SAF
    [7] - SAF
    [8] - SAF
    No statistical analyses for this end point

    Other pre-specified: Appearance of the Formulation Assessed by Questionnaire

    Close Top of page
    End point title
    Appearance of the Formulation Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding appearance immediately after study drug administration. Subjects were asked the question as ‘I like the appearance of the medium’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [9]
    16 [10]
    16 [11]
    Units: subjects
        Disliked
    0
    3
    3
        Neutral
    6
    7
    8
        Liked
    10
    6
    5
    Notes
    [9] - SAF
    [10] - SAF
    [11] - SAF
    No statistical analyses for this end point

    Other pre-specified: Taste of the Formulation Assessed by Questionnaire

    Close Top of page
    End point title
    Taste of the Formulation Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding taste immediately after study drug administration. Subjects were asked the question as ‘I like the taste after swallowing’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [12]
    16 [13]
    16 [14]
    Units: subjects
        Disliked
    1
    4
    3
        Neutral
    2
    8
    5
        Liked
    13
    4
    8
    Notes
    [12] - SAF
    [13] - SAF
    [14] - SAF
    No statistical analyses for this end point

    Other pre-specified: Smell of the Formulation Assessed by Questionnaire

    Close Top of page
    End point title
    Smell of the Formulation Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding smell immediately after study drug administration. Subjects were asked the question as ‘I like the smell of the medium’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [15]
    16 [16]
    16 [17]
    Units: subjects
        Disliked
    0
    2
    2
        Neutral
    4
    12
    11
        Liked
    12
    1
    3
    Notes
    [15] - SAF
    [16] - SAF
    [17] - SAF
    No statistical analyses for this end point

    Other pre-specified: Overall Impression of the Formulation Assessed by Questionnaire

    Close Top of page
    End point title
    Overall Impression of the Formulation Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding overall impression immediately after study drug administration. Subjects were asked the question as ‘I like the medium overall’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [18]
    16 [19]
    16 [20]
    Units: subjects
        Disliked
    0
    2
    1
        Neutral
    3
    5
    5
        Liked
    13
    9
    10
    Notes
    [18] - SAF
    [19] - SAF
    [20] - SAF
    No statistical analyses for this end point

    Other pre-specified: Texture of the Formulation Assessed by Questionnaire

    Close Top of page
    End point title
    Texture of the Formulation Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding texture immediately after study drug administration. Subjects were asked the question as ‘texture like sand, sticky, dry, creamy and strange (unlike any of the above mentioned) or other feeling’, where subjects were selected their response from one of the five items: ‘completely disagree’, ‘somewhat disagree’, ‘neutral’, ‘somewhat agree’ and ‘completely agree’. In the below table, the response for categories ‘completely disagree’, ‘somewhat disagree’ were summarized under "disliked" and response from categories ‘somewhat agree’ and ‘completely agree’ were summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [21]
    16 [22]
    16 [23]
    Units: subjects
        Sand: Disliked
    16
    15
    16
        Sand: Neutral
    0
    0
    0
        Sand: Liked
    0
    1
    0
        Sticky: Disliked
    13
    11
    11
        Sticky: Neutral
    1
    1
    0
        Sticky: Liked
    2
    4
    5
        Dry: Disliked
    16
    15
    16
        Dry: Neutral
    0
    1
    0
        Dry: Liked
    0
    0
    0
        Creamy: Disliked  
    6
    2
    2
        Creamy: Neutral
    4
    4
    4
        Creamy: Liked  
    6
    10
    10
        Strange: Disliked 
    14
    15
    14
        Strange: Neutral
    1
    0
    1
        Strange: Liked 
    1
    1
    1
    Notes
    [21] - SAF
    [22] - SAF
    [23] - SAF
    No statistical analyses for this end point

    Other pre-specified: Whether Oro-dispersible Tablets are Palatable and Swallowable Assessed by Questionnaire

    Close Top of page
    End point title
    Whether Oro-dispersible Tablets are Palatable and Swallowable Assessed by Questionnaire
    End point description
    Subjects completed a questionnaire regarding palatable and swallowable immediately after study drug administration. Subjects were asked the question as ‘It was easy for me to swallow’, where subjects were selected their response from one of the two items: ‘somewhat disagree’, and ‘completely agree’. In the below table, the response for category ‘somewhat disagree’ was summarized under "disliked" and response from category ‘completely agree’ was summarized under "liked".
    End point type
    Other pre-specified
    End point timeframe
    Immediately after study drug administration
    End point values
    Finerenone 20 mg Crushed Tablet Fasted (Treatment B) Finerenone 20 mg Suspension Fasted (Treatment C) Finerenone 20 mg Suspension Fed (Treatment D)
    Number of subjects analysed
    16 [24]
    16 [25]
    16 [26]
    Units: subjects
        Disliked
    0
    0
    0
        Neutral
    0
    0
    0
        Liked
    16
    16
    16
    Notes
    [24] - SAF
    [25] - SAF
    [26] - SAF
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    From the start of study drug administration up to 1 week after the last drug administration (Day 16)
    Assessment type
    Non-systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.1
    Reporting groups
    Reporting group title
    Finerenone, 20mg Intact Tablet Fasted
    Reporting group description
    Subjects received a single oral dose of 20 mg finerenone intact film-coated tablet in fasted state during any intervention period.

    Reporting group title
    Finerenone, 20mg Crushed Tablet Fasted
    Reporting group description
    Subjects received a single oral dose of 20 mg finerenone crushed and re-suspended film-coated tablet in fasted state during any intervention period.

    Reporting group title
    Finerenone, 20mg Suspension Fasted
    Reporting group description
    Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) in fasted state during any intervention period.

    Reporting group title
    Finerenone, 20mg Suspension Fed
    Reporting group description
    Subjects received a single oral dose of 20 mg finerenone suspension (10 mL) after a standardized high-fat, high-calorie American breakfast in fed state during any intervention period.

    Serious adverse events
    Finerenone, 20mg Intact Tablet Fasted Finerenone, 20mg Crushed Tablet Fasted Finerenone, 20mg Suspension Fasted Finerenone, 20mg Suspension Fed
    Total subjects affected by serious adverse events
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         number of deaths (all causes)
    0
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Finerenone, 20mg Intact Tablet Fasted Finerenone, 20mg Crushed Tablet Fasted Finerenone, 20mg Suspension Fasted Finerenone, 20mg Suspension Fed
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    2 / 16 (12.50%)
    2 / 16 (12.50%)
    3 / 16 (18.75%)
    4 / 16 (25.00%)
    Investigations
    Amylase increased
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
         occurrences all number
    0
    0
    0
    1
    C-reactive protein increased
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
         occurrences all number
    1
    1
    0
    1
    Lipase increased
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    2 / 16 (12.50%)
         occurrences all number
    0
    0
    0
    2
    White blood cell count increased
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
         occurrences all number
    0
    1
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Dysphonia
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
         occurrences all number
    0
    0
    0
    1
    Nasal congestion
         subjects affected / exposed
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         occurrences all number
    1
    0
    0
    0
    Oropharyngeal pain
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Nervous system disorders
    Headache
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    1 / 16 (6.25%)
         occurrences all number
    0
    2
    0
    2
    Gastrointestinal disorders
    Nausea
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Vomiting
         subjects affected / exposed
    0 / 16 (0.00%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         occurrences all number
    0
    1
    0
    0
    Infections and infestations
    Nasopharyngitis
         subjects affected / exposed
    0 / 16 (0.00%)
    0 / 16 (0.00%)
    2 / 16 (12.50%)
    0 / 16 (0.00%)
         occurrences all number
    0
    0
    2
    0
    Rhinitis
         subjects affected / exposed
    1 / 16 (6.25%)
    1 / 16 (6.25%)
    0 / 16 (0.00%)
    0 / 16 (0.00%)
         occurrences all number
    1
    1
    0
    0

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? No

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    Occurrence of "±” in relation with geometric CV is auto-generated and cannot be deleted. Decimal places were automatically truncated if last decimal equals zero.
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2019 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA